Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Apatinib and Temozolomide in Advanced Acral Melanoma
NCT04397770Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in acral lentiginous melanoma (ALM), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT04397770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397770.